|
Feb 15
|
Dividend Investor With $1.05 Million In Stocks And $36,600 Annual Payout Shares Portfolio – 'Could These Picks Set You Up for Life?'
|
|
Feb 14
|
Pfizer’s Talzenna gains 14-months OS lead over mCRPC SoC
|
|
Feb 14
|
Pharma Stock Roundup: NVS, ABBV M&A Deals, FDA Nod to RHHBY, PFE Drugs
|
|
Feb 13
|
Pfizer’s TALZENNA® in Combination with XTANDI® Improves Survival Outcomes in Metastatic Castration Resistant Prostate Cancer
|
|
Feb 13
|
Investor With $1M Portfolio Earning $61,000 In Dividends Reveals 10 Top Picks, Says 'I'm Considering Aggressive Growth – What Would You Do?'
|
|
Feb 13
|
ViiV Healthcare and the pan-Canadian Pharmaceutical Alliance (pCPA) successfully finalize negotiations for APRETUDE for HIV-1 Pre-Exposure Prophylaxis
|
|
Feb 13
|
Are Investors Being Too Paranoid About Pfizer Stock?
|
|
Feb 13
|
3 Brand-Name, Ultra-High-Yield Dividend Stocks Patient Investors Can Confidently Buy With $300 Right Now
|
|
Feb 12
|
U.S. FDA Approves Pfizer’s ADCETRIS® Combination Regimen for the treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma
|
|
Feb 12
|
Earnings To Watch: Zoetis (ZTS) Reports Q4 Results Tomorrow
|
|
Feb 12
|
Organon (OGN) Q4 Earnings Report Preview: What To Look For
|
|
Feb 12
|
Q4 2024 Arvinas Inc Earnings Call
|
|
Feb 11
|
Pfizer/Astellas Tout Encouraging Data From Keytruda Combo Regime In Urothelial Cancer Showing 49% Reduction In Death Risk Vs. Chemo
|
|
Feb 11
|
Pfizer Inc. (PFE) Is a Trending Stock: Facts to Know Before Betting on It
|
|
Feb 10
|
Pfizer, Astellas Cite 'Durable Benefit' in More Trial Results of Padcev Plus Keytruda in Urothelial Cancer
|
|
Feb 10
|
Trump Curbs Enforcement of Antibribery Law
|
|
Feb 10
|
Pfizer and Astellas’ PADCEV® (enfortumab vedotin-ejfv) plus KEYTRUDA® (pembrolizumab) Shows Long-Term Efficacy in First-Line Treatment of Locally Advanced or Metastatic Urothelial Cancer (la/mUC)
|
|
Feb 10
|
Super Bowl Ad Results: AI Can’t Compete With Sentimental Stories
|
|
Feb 9
|
Pfizer Inc. (NYSE:PFE) is favoured by institutional owners who hold 68% of the company
|
|
Feb 9
|
Is Now a Good Time to Buy the Dip on Pfizer?
|